Current status of glycopeptides resistance among MRSA isolates

ISBN-13: 9783843366304 / Angielski / Miękka / 2010 / 132 str.

Kaleem, Fatima

Opis

Vancomycin has been widely used in the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The emergence of vancomycin-intermediate and vancomycin resistant Staphylococcus aureus (VISA and VRSA, respectively) in various parts of the world has been of great concern in clinical settings. This study was performed to monitor the status of vancomycin susceptibility against MRSA in our set up. All non duplicate MRSA isolates recovered from various wards of Military Hospital Rawalpindi were subjected to the detection of minimum inhibitory concentrations (MICs) of vancomycin using E- strips. Isolates having standard vancomycin MICs equal or greater than 1 ug/ mL were subjected to the detection of Glycopeptide Intermediate Staphylococcus aureus (GISA) / heterogeneous Glycopeptide Intermediate Staphylococcus aureus (h GISA) by using GRD (Glycopeptide Resistance Detection) E- Test. Results were analyzed to evaluate the possible presence of VISA, VRSA, GISA and h GISA.

O autorze

Did MBBS from Islamic International Medical College, Rawalpindi, Pakistan in year 2005. Currently doing MPhil-PhD in Microbiology from National University of Sciences and Technology, Pakistan. Till date 4 National and 4 International Publications.Research interests are multidrug resistant and emerging nosocomial pathogens.